[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611806":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":42,"centralContacts":47,"locations":53,"responsibleParty":147,"collaborators":42,"id":149,"slug":42,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":42,"eligibilityCriteria":154,"healthyVolunteers":155,"sex":156,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":42,"studyType":162,"phases":163,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":101,"whyStopped":42,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},{"fullName":5,"class":6},"Prana Therapies Inc","INDUSTRY",[8,14,20,24,28,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1, Part 1: SAD Cohorts: Active Drug","EXPERIMENTAL","Healthy volunteers will receive a single dose of PRA-216 in a dose escalation format.",[13],"Drug: PRA-216",{"label":15,"type":16,"description":17,"interventionNames":18},"Phase 1, Part 1: SAD Cohorts: Placebo","PLACEBO_COMPARATOR","Healthy volunteers will receive a single dose of placebo",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Phase 1, Part 2: MAD Cohort: Active Drug","Healthy volunteers will receive repeated doses of PRA-216 in a dose escalation format.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Phase 1, Part 2 MAD Cohort: Placebo Comparator","Healthy volunteers will receive repeated doses of placebo comparator.",[19],{"label":29,"type":10,"description":30,"interventionNames":31},"Phase 2a: Participants with mild to moderate asthma-active drug","Participants with mild to moderate asthma will be randomized to receive repeat doses of PRA-216.",[13],{"label":33,"type":16,"description":34,"interventionNames":35},"Phase 2a: Participants with mild to moderate asthma-placebo","Participants with mild to moderate asthma will be randomized to receive repeat doses of placebo.",[19],[37,43],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","PRA-216","biologic",[9,21,29],null,{"type":38,"name":44,"description":45,"armGroupLabels":46,"otherNames":42},"Placebo","matching placebo for PRA-216",[15,25,33],[48],{"name":49,"role":50,"phone":51,"phoneExt":42,"email":52},"Linear site contact","CONTACT","+61 (0)8 6382 5110","enquiries@linear.org.au",[54,72,87,100,113,124,139],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Emertitus Research Sydney","NOT_YET_RECRUITING","Botany","New South Wales","2019","Australia",{"type":62,"coordinates":63},"Point",[64,65],151.19591,-33.94599,{"lat":65,"lon":64},[68],{"name":69,"role":50,"phone":70,"phoneExt":42,"email":71},"Ronald Mak, MD","0289648186","ronaldmak@emeritusresearch.com",{"facility":73,"status":56,"city":74,"state":75,"zip":76,"country":60,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Emeritus Research Camberwell","Camberwell","Victoria","3124",{"type":62,"coordinates":78},[79,80],145.0694,-37.84205,{"lat":80,"lon":79},[83],{"name":84,"role":50,"phone":85,"phoneExt":42,"email":86},"Sam Francis, MD","0395096166","samfrancis@emeritusresearch.com",{"facility":88,"status":56,"city":89,"state":90,"zip":91,"country":60,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Linear","Joondalup","Western Australia","6027",{"type":62,"coordinates":93},[94,95],115.76835,-31.74445,{"lat":95,"lon":94},[98],{"name":42,"role":50,"phone":99,"phoneExt":42,"email":52},"011 61 88 6382 5110",{"facility":88,"status":101,"city":102,"state":90,"zip":103,"country":60,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"RECRUITING","Nedlands","6009",{"type":62,"coordinates":105},[106,107],115.8073,-31.98184,{"lat":107,"lon":106},[110],{"name":111,"role":50,"phone":112,"phoneExt":42,"email":52},"site contact","08 6382 5110",{"facility":114,"status":56,"city":115,"state":116,"zip":117,"country":118,"cosmosGeoPoint":42,"geoPoint":42,"contacts":119},"PCRN Waikato, Nawton","Hamilton","Auckland","3200","New Zealand",[120],{"name":121,"role":50,"phone":122,"phoneExt":42,"email":123},"Enrollment Coordinator","+64 07 960 2123","enquiries@clinicaltrialswaikato.co.nz",{"facility":125,"status":56,"city":126,"state":116,"zip":127,"country":118,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Pacific Clinical Research Network-Auckland","Takapuna","0622",{"type":62,"coordinates":129},[130,131],174.77583,-36.79167,{"lat":131,"lon":130},[134,137],{"name":121,"role":50,"phone":135,"phoneExt":42,"email":136},"+64 9 242 3321","Adminauckland@pcrn.co.nz",{"name":42,"role":50,"phone":42,"phoneExt":42,"email":138},"Auckland@pcrn.co.nz",{"facility":140,"status":56,"city":141,"state":116,"zip":142,"country":118,"cosmosGeoPoint":42,"geoPoint":42,"contacts":143},"PCRN Wellington, Ebdentown","Upper Hutt","5018",[144],{"name":121,"role":50,"phone":145,"phoneExt":42,"email":146},"+64 4 9201800","clinicaltrials@uhhc.co.nz",{"type":148,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100611806",false,"NCT07245368","Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma","A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending and Multiple Ascending Dose Study Investigating PRA-216 in Healthy Volunteers Followed by a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study in Participants With Mild-to-Moderate Asthma","Phase 1\n\nInclusion Criteria:\n\n* Age 18-65\n* Must be in good health with no significant medical history\n* Willing and able to attend all study visits, comply with study requirements\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Evidence of clinically significant condition or disease\n* Any physical or psychological condition that prohibits study completion\n* Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism, and\u002For smoking or nicotine-containing product use within 3 months prior to the first dose of study agent\n* History of severe allergic reactions or hypersensitivity\n* Donation or loss of ≥ 1 unit of whole blood or plasma within 2 months prior to dosing\n\nPhase 2a\n\nInclusion criteria:\n\n* Age 18-65\n* Must be in good health with no significant medical history\n* Willing and able to attend all study visits, comply with study requirements.\n* Able and willing to provide written informed consent\n* Documented asthma diagnosis prior for at least 12 months prior to screening.\n* Symptomatic asthma\n* Currently receiving maintenance asthma medications\n\nExclusion Criteria:\n\n* Evidence of clinically significant condition or disease\n* Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism, and\u002For smoking or nicotine-containing product use within 3 months prior to the first dose of study agent\n* Donation or loss of ≥ 1 unit of whole blood or plasma within 2 months prior to dosing\n* History of severe allergic reactions or hypersensitivity\n* Current or former smoker with a smoking history of ≥10 pack-years\n* Receipt of immunosuppressant therapies or biologic therapy for asthma within 6 months of screening\n* Other investigational agent(s) within 30 days of dosing",true,"ALL","18 Years","65 Years",{"count":160,"type":161},96,"ESTIMATED","INTERVENTIONAL",[164,165],"PHASE1","PHASE2","Phase 1 of this study will consist of 2 parts\n\n* Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC).\n* Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously.\n\nPhase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.",[168],"Mild to Moderate Asthma",[170,171,172,173,174],"healthy volunteers","pharmacodynamics","immunogenicity","asthma","pharmacokinetics","2026-03-18",{"date":177,"type":178},"2026-03-20","ACTUAL",{"date":180,"type":178},"2025-11-04",{"date":182,"type":161},"2027-01-31",{"name":5,"class":6},7]